Coagulopathy is an evident complication of COVID-19 with predominance of a
prothrombotic state. Platelet activation plays a key role. The terms “hyper-reactivity” and …

Given the limited information on the coagulation abnormalities of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in pediatric patients, we designed a systematic …

Background. Most evidence regarding anticoagulation and COVID‐19 refers to the
hospitalization setting, but the role of oral anticoagulation (OAC) before hospital admission …

Aims This study aimed to evaluate the efficacy and safety of regdanvimab, an anti‐SARS‐
COV‐2 monoclonal antibody approved by the European Medicines Agency in November …

ABSTRACT COVID-19 is a contagious, severe acute respiratory disease caused by the
coronavirus named SARS-CoV-2. In this review, we have updated the nature and evolution …

An antiparallel, functional RNA G-quadruplex of the 2′–5′-linked thrombin-binding
aptamer (iso-rTBA) is reported for the first time. It can inhibit clotting and is remarkably stable …

Since the beginning of the COVID-19 pandemic in 2020, as of 5: 35 pm CET, 10th February,
2023, there have been 755.385. 709 confirmed cases of COVID-19, including 6.833. 388 …

Abstract Background (p-BthTX-I) 2 K, a dimeric analog peptide derived from the C-terminal
region of phospholipase A2-like bothropstoxin-I (p-BthTX-I), is resistant to plasma …

Remdesivir is a direct-acting anti-viral agent. It was originally evaluated against filoviruses.
However, during the COVID-19 pandemic, it was investigated due to its anti-viral activities …

Background and Objectives: Action, not fear, is the path forward in the coronavirus infectious
disease 2019 (COVID-19) pandemic. Since early 2020, the world's nations have faced …